Pfizer Announces Top-line Results From Phase 3 Trial Of INLYTA® (axitinib) In Treatment-Naïve Patients With Advanced Renal Cell Carcinoma
Pfizer Inc. announced today that a Phase 3 study of INLYTA
(axitinib) did not meet its primary endpoint of demonstrating
statistically significantly longer progression-free survival (PFS),
versus sorafenib, in...